PAT up 31% in Q1FY27, TGA Australia and EU-GMP approvals secured, Rs 200 crore cash on balance sheet, near debt-free
Not every compelling pharmaceutical investment story involves blockbuster drugs or billion-dollar pipelines. Sometimes it involves a forty-five-year-old Ahmedabad-based company quietly building a 600-product branded-generic franchise across fifteen therapeutic areas, securing regulated market approvals, growing exports across 60 countries heading toward 90, and trading at approximately 14.5x trailing earnings while the pharma sector median sits at 30x.
Lincoln Pharmaceuticals is that story. Angel One initiates coverage with a BUY rating and a target price of Rs 845 — implying 39% upside from the current market price of Rs 610 — valuing the stock at approximately 15x FY27 EPS of Rs 56.
Momentum Re-Accelerating
Lincoln has opened FY27 strongly. Q1 consolidated net profit rose 30.9% year-on-year to Rs 36 crore. Total income grew 19% to Rs 202 crore. EBITDA rose 32% to Rs 52 crore. Core operating profit — excluding other income — grew approximately 15% year-on-year on approximately 15% revenue growth, keeping operating margins stable near 15.5%.
The company holds more than Rs 200 crore of cash on a near debt-free balance sheet, and the other income contribution from this treasury will naturally feature in the reported numbers. The key monitorable is the pace of core operating delivery — and Q1FY27 suggests that this is tracking at a healthy 15% growth rate independently of the treasury contribution.
The Branded-Generic Franchise
Lincoln’s product portfolio spans 600+ formulations across 15+ therapeutic areas — a breadth that provides meaningful protection against the therapeutic concentration risk that affects more focused generic companies. The strongest domestic franchises are in cardiac, diabetic, dermatology, gynaecology, ENT and anti-infective segments — a mix that spans both acute and chronic therapies and positions the company well as India’s chronic-disease burden grows with an ageing and urbanising population.
The shift toward higher-value products and chronic-therapy formulations is a deliberate strategic direction. “Lincoln is steadily lifting the share of higher-value products and regulated-market exports,” the Angel One report notes — a product mix improvement that, alongside modest operating leverage, is expected to keep EBITDA margins around 19-20% over FY27-29. The Cephalosporin manufacturing block adds a specific capability in a high-demand antibiotic category that supports both domestic revenue and export potential.
The Re-Rating Catalyst
The most strategically significant recent development at Lincoln is the regulatory approvals secured for high-value markets. TGA Australia and EU-GMP approvals open access to developed-world regulated markets — environments where quality standards are rigorous, price realisations are substantially higher than semi-regulated markets, and once established, relationships tend to be sticky and long-duration.
“Exports are emerging as a key growth and margin lever, with the company expanding from 60 towards 90 countries and having secured TGA Australia and EU-GMP approvals that open access to higher-value regulated markets,” the report states. The Canada expansion — specifically mentioned in the Q1FY27 management commentary — adds another regulated market foothold. As the contribution from regulated markets grows within the export mix, both the revenue quality and the margin profile of Lincoln’s international business will improve meaningfully.
The Rs 1,000 Crore Target — Credible and Achievable
Management has set a specific and time-bound revenue target: Rs 1,000 crore within the next three years from a FY26 base of Rs 704 crore. This implies approximately 12-13% annual revenue growth — in line with the 15-18% annual growth management targets, though the lower end of the range. Angel One’s estimates are broadly supportive of this trajectory. “Management targets approximately 15-18% annual growth and Rs 1,000 crore revenue over three years,” the report notes — and the combination of a deepening domestic chronic-therapy franchise, expanding regulated-market exports and the Cephalosporin block contributing incrementally makes this a credible rather than aspirational target.
The balance sheet provides the financial runway to pursue this growth without stress. More than Rs 200 crore of cash with a near debt-free position and a CRISIL A/Stable/A1 credit rating means Lincoln can invest in distribution, product development and potentially a greenfield manufacturing facility in Gujarat — which management has flagged as an option — without requiring equity dilution or taking on meaningful debt. “A near debt-free balance sheet with more than Rs 200 crore of cash provides significant financial stability and the company is open for suitable growth opportunities,” the report notes.
The Valuation Gap
At approximately 14.5x trailing earnings, Lincoln trades at a steep discount to the pharma sector median of approximately 30x. This discount has historically reflected the company’s smaller scale, limited analyst coverage and the absence of a high-profile product or market story. Each of these factors is changing. Scale is growing toward Rs 1,000 crore. Regulated market approvals are adding a quality narrative. And Angel One’s initiation is the beginning of a coverage expansion that typically precedes re-rating for underfollowed mid and small cap companies.
“At approximately 14.5x trailing earnings, Lincoln trades at a steep discount to the approximately 30x pharma-sector median, leaving room for re-rating as earnings compound,” the report states.
Scorecard
| Metric | Value |
|---|---|
| Current Market Price | Rs 610 |
| Target Price | Rs 845 |
| Upside | 39% |
| Rating | BUY (Initiation) |
| Valuation | ~15x FY27E EPS |
| FY27E EPS | Rs 56 |
| Q1FY27 PAT Growth | +30.9% YoY |
| Q1FY27 Revenue Growth | +19% YoY |
| FY26 Revenue | Rs 704 crore |
| 3-Year Revenue Target | Rs 1,000 crore |
| Cash on Balance Sheet | Rs 200 crore+ |
| Net Debt | Near zero |
| Export Countries | 60+ (targeting 90) |
| Regulatory Approvals | TGA Australia, EU-GMP |
| Trailing P/E | ~14.5x (vs sector ~30x) |